SugaROx raises £2.5m seed to fund trials and regulatory data for trehalose-6-phosphate
This article covers SugaROx, a UK-based biotech startup, raising £2.5m in a seed funding round to advance commercialisation of a trehalose-6-phosphate based biostimulant and scale up field trials. The funding aims to generate regulatory data and support launches in the UK, EU and US for key crops including wheat, barley, soybean and maize.
SugaROx, a UK-based biotech startup, has raised £2.5 million in a seed funding round to advance commercialisation of a trehalose-6-phosphate based biostimulant and scale up field trials. The funding is intended to generate regulatory data and support launches in the UK, EU and US for key crops including wheat, barley, soybean and maize.
Why it matters
Biostimulants are one of the faster-growing segments in crop inputs, with an estimated compound annual growth rate of around 12%. The sector promises alternatives to conventional agrochemicals by enhancing plant performance through biological pathways, but it has been held back by delivery challenges. If SugaROx’s approach to getting active molecules into plant cells proves reliable at scale, it could improve yield and quality for major cereal and row crops and create commercial momentum for biological inputs.
Inside the product
SugaROx’s lead product is based on a proprietary formulation of the natural plant sugar trehalose-6-phosphate. The company says its patented delivery technology enables biologically active molecules to cross plant cell walls and membranes—overcoming a common limitation of standard agronomic methods such as foliar sprays.
The first molecule in the pipeline targets a so-called famine-signalling enzyme, promoting movement of carbon and nutrients towards grain filling. The intended result is improved yield and grain quality, particularly in wheat and barley in Europe and in soybean and maize in North America. The company plans to use the funding to expand research and development, ramp up global field trials, and produce the data required for regulatory approval ahead of a planned UK launch in 2027–2028 and EU/US expansion between 2028 and 2030.
Who are the investors?
The round is led by The Mosaic Company, which previously backed SugaROx with a £400,000 investment in a 2025 seed round. The latest cheque is positioned to deepen field validation and support the regulatory work needed for commercial roll-out across multiple markets.
In the announcement, Jeff Wheeler, VP Biosciences at The Mosaic Company, said:
SugaROx is advancing a new category of precision biostimulants that aligns closely with our approach at Mosaic Biosciences, where we are building a science-backed portfolio of solutions that support the biology of plants and soil. We are pleased to support the team as they expand field validation and progress towards commercialisation.
If you're researching potential backers in this space:
- Explore our list of biotech venture capital firms in the UK
- Browse our directory of biotech angel investors in the UK
Founder perspective
In the announcement, Mark Robbins, CEO at SugaROx, said:
We’re delighted to deepen our collaboration with The Mosaic Company as we move closer to commercialisation. Their continued support is a strong validation of both our science and our ability to deliver a differentiated product in a fast-growing market.
The bigger picture
The financing highlights continued investor interest in biological crop inputs and the potential commercialisation pathway for UK agri-biotech. For growers and input manufacturers alike, reliable delivery mechanisms for bioactive molecules would be a technical step-change, not just a new product category.
The deal also reflects the lifecycle challenge for UK startups in agri-biotech: converting laboratory efficacy into consistent field performance and then navigating a patchwork of regulatory regimes across the UK, EU and US. The planned field trials and data generation funded by this round will be pivotal to whether SugaROx can meet those regulatory requirements and reach farmers at scale.
This investment is another data point in a broader trend of funding for UK and European agri-biotech innovation, where commercial partners and industry players are increasingly backing companies that can demonstrate clear regulatory and field validation pathways.
They've invested in SugaROx
Get to know these biotech investors
Click here for a full list of 7,589+ startup investors in the UK